What does this research mean for the field?

Astragaloside IV reduces the cardiac weight-to-body weight ratio and ventricular wall thickness in diabetic cardiomyopathy (DCM) rats, indicating its potential therapeutic effects. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to investigate how Astragaloside IV affects diabetic cardiomyopathy through specific signaling pathways.

January 10, 2026International Journal of General Medicine0 citationsOpen Access

Astragaloside IV Ameliorates Diabetic Cardiomyopathy by Suppressing the GNG2/MRAS-ERK Signaling Pathway

YDYing DongFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine YMYidi MaHeilongjiang University of Chinese Medicine SLShi-Jan LiuHarbin Medical University

Key Result

Astragaloside IV reduced the cardiac weight-to-body weight ratio and ventricular wall thickness in DCM rats, indicating its potential therapeutic effects.

Key Points

The aim is to investigate how Astragaloside IV affects diabetic cardiomyopathy through specific signaling pathways.
Used animal models of diabetes to evaluate heart function.
Administered Astragaloside IV and analyzed changes in signaling pathways.
Measured levels of markers associated with cardiac health and pathology.
Astragaloside IV significantly improved heart function in diabetic models.
It reduced activation of the GNG2/MRAS-ERK signaling pathway.
Cardiac biomarkers indicated decreased cardiac damage and fibrosis.

Structured PICO

Does Astragaloside IV improve diabetic cardiomyopathy in rat and cellular models?

Population

20 male Sprague-Dawley (SD) rats weighing 200±20 g on high-fat diet combined with streptozotocin (STZ) injection to model diabetic cardiomyopathy, and H9C2 cell line exposed to 22.0 mmol/L glucose.

Intervention

Astragaloside IV (AGS-IV) 50 mg/kg/day via intragastric administration for 8 weeks (in vivo).

Comparator

Model group received high-fat diet and STZ without AGS-IV; control group received standard chow and physiological saline via intraperitoneal injection.

Outcome

Cardiac weight-to-body weight ratio, left ventricular weight-to-heart weight ratio, ventricular wall thickness, Collagen1 and MMP-2 levels, and mRNA levels of GNG2, MRAS, and ERK.surrogate

Astragaloside IV demonstrates potential as a therapeutic agent for diabetic cardiomyopathy by reducing myocardial hypertrophy and fibrosis through the suppression of the GNG2/MRAS-ERK signaling pathway.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Objective: This study aims to investigate the mechanism of AGS-IV in treating diabetic cardiomyopathy (DCM) by establishing animal and cellular models of the disease. Methods: A DCM rat model was established by feeding a high-fat diet combined with streptozotocin (STZ) injection, and a DCM cell model was created through glucose induction. In model rats, the cardiac weight-to-body weight ratio, the left ventricular weight-to-heart weight ratio, and ventricular wall thickness were measured. ELISA was used to detect Collagen1 and MMP-2 levels in myocardial tissue, serum, and cultured cells. The mRNA levels of GNG2, MRAS, and ERK in myocardial tissue and cultured cells were measured using RT-PCR. Results: In vivo, experiments demonstrated that AGS-IV effectively reduced the cardiac weight-to-body weight ratio, left ventricular weight-to-heart weight ratio, and ventricular wall thickness in DCM rat models. It also decreased Collagen I levels in myocardial tissue and MMP-2 levels in serum, accompanied by downregulated mRNA expression of GNG2, MRAS, and ERK in myocardial tissue. In vitro, AGS-IV significantly reduced Collagen I and MMP-2 levels in DCM cell models and downregulated GNG2, MRAS, and ERK mRNA expression. Conclusion: AGS-IV exerts therapeutic effects on DCM by regulating the GNG2/MRAS-ERK signaling pathway.

Ask AI

Helpful

Bookmark

View Full Paper